Co-Diagnostics, Inc. (CODX) News
Filter CODX News Items
CODX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CODX News Highlights
- CODX's 30 day story count now stands at 6.
- Over the past 15 days, the trend for CODX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about CODX are DX, CM and AMP.
Latest CODX News From Around the Web
Below are the latest news stories about CO-DIAGNOSTICS INC that investors may wish to consider to help them evaluate CODX as an investment opportunity.
Co-Diagnostics Third Quarter 2022 Earnings: Misses ExpectationsCo-Diagnostics ( NASDAQ:CODX ) Third Quarter 2022 Results Key Financial Results Revenue: US$5.09m (down 83% from 3Q... |
Co-Diagnostics, Inc. to Host Booth at MEDICA 2022 Trade Fair in Düsseldorf, GermanyCo-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth this week at the MEDICA 2022 trade fair in Düsseldorf, Germany from 15-17 November. |
Co-Diagnostics, Inc.'s (NASDAQ:CODX) Intrinsic Value Is Potentially 23% Below Its Share PriceIn this article we are going to estimate the intrinsic value of Co-Diagnostics, Inc. ( NASDAQ:CODX ) by estimating the... |
Co-Diagnostics, Inc. Reports Third Quarter 2022 Financial ResultsCo-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the third quarter ended September 30, 2022. |
Co-Diagnostics, Inc. to Host Booth at AMP This Week in Phoenix, AZCo-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company is hosting a booth this week at the Association for Molecular Pathology ("AMP") annual expo, held November 1-5 in Phoenix, AZ. |
Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific OfficerCo-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Mark Poritz, PhD as the Company's new Chief Scientific Officer ("CSO"). |
CO-DIAGNOSTICS, INC. ANNOUNCES THIRD QUARTER 2022 EARNINGS RELEASE DATE AND WEBCASTCo-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2022 results on Thursday, November 10, 2022, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. EDT to discuss its financial results with analysts and institutional investors. Management on the call will include Dwight Egan, Chief Executi |
Co-Diagnostics, Inc. to Host Booth at Medlab Africa on Oct 26-28 in South AfricaCo-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting a booth this week at Africa Health/Medlab Africa in Johannesburg, South Africa on October 26-28, 2022. |
Co-Diagnostics, Inc. to Host Booths at Conferences in Washington, D.C. and Bangkok, ThailandCo-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting booths this week at IDWeek 2022 in Washington, D.C., and at Asia Health/Medlab Asia in Bangkok, Thailand. |
Co-Diagnostics' (NASDAQ:CODX) investors will be pleased with their strong 225% return over the last three yearsThe last three months have been tough on Co-Diagnostics, Inc. ( NASDAQ:CODX ) shareholders, who have seen the share... |